DIAGNOS Inc. (DGNOF) Stock Price & Analysis
DIAGNOS Inc. (DGNOF) — price $0.17 (-21.30%), as of the Nov 19, 2026 trading session; market cap $20.6M.
Educational signal · not a buy or sell recommendation · How to read this
DIAGNOS Inc. · DGNOF
DIAGNOS Inc. specializes in software-based healthcare services, primarily Computer Assisted Retina Analysis (CARA), a tool for detecting diabetic retinopathy. The company operates in multiple countries, offering both diagnostic services and consulting in data analysis and artificial intelligence.
Price as of Nov 19, 2026
Key Statistics
Not scored: this is a debt/preferred or other non-common instrument, or its reported market value does not match its share basis.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.17 | |
| Change on the day | -21.30% | |
| 52-week range | $0.1282 – $0.3823 | |
| Market capitalisation | $20.6M | — |
| Shares traded on the day | 6.5K |
Price & events
Other perspectives
Council score for DIAGNOS (DGNOF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is DIAGNOS (DGNOF), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. DIAGNOS Inc. (DGNOF) is the company analyzed here. It employs 22 people and is led by Andre Larente. In Q4 FY2026 it reported revenue of C$15,750 and net income of -C$1M. The market values it at $20.6M.
What do the latest results show for DIAGNOS (DGNOF)?
Short answer · as of
The most recent reported quarter, Q4 FY2026, carried revenue of C$15,750. Against analyst estimates the company has EPS beat 1 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2026 | C$15,750 | -C$1M | -C$0.01 (diluted) |
| Q3 FY2026 | C$15,193 | -C$1M | -C$0.01 (diluted) |
| Q2 FY2026 | C$15,159 | -C$1M | -C$0.01 (diluted) |
| Q1 FY2026 | C$19,402 | -C$1M | -C$0.01 (diluted) |
What are the financial strengths and risks for DIAGNOS (DGNOF)?
Short answer · as of
The distress and quality screens read Altman Z -26.89 · Piotroski F 3. Trailing ratios: current ratio 1.49 · earnings yield -10.5% · free-cash-flow yield -8.9%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -26.89 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held DGNOF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported DGNOF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Investor Questions: DGNOF Stock
These answers are editorial: 1 of these 1 answer is drawn from the DGNOF research dossier (written Mar 16, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.
What are the main risks for DGNOF?
The main risks for DIAGNOS Inc. include its negative financial performance, as indicated by its negative P/E ratio and profit margin, which raises concerns about its financial sustainability. Competition from larger healthcare companies with more resources poses a threat to its market share. Regulatory changes in healthcare could affect the adoption of its AI-powered diagnostic tools.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 7 from Financial Modeling Prep (FMP) and 7 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com